Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWeill Medical College of Cornell University
About this trial
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Eligibility criteria
Qualifiers
Biologically female
Age ≥ 18
Obesity as defined by current BMI ≥ 30 kg/m²
Postmenopausal as defined by one or more of the following
Disqualifiers
Stage IV breast cancer
Concomitant use of CDK inhibitors
Concomitant use of antiHER2 therapy
The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
Trial design
Treatments tested in this trial
- Tirzepatide
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Weill Medical College of Cornell University
Lead sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Source ClinicalTrials.gov